Ara C

DRUG3 trials

Sponsors

Baylor College of Medicine, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Conditions

CLASSICAL HODGKIN LYMPHOMACancerHodgkin LymphomaLeukemiaLymphomaLymphoma, HodgkinLymphoma, Non-HodgkinMyeloproliferative Disorders

Phase 1

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

CompletedNCT02243436

Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaCLASSICAL HODGKIN LYMPHOMA

Start: 2014-11-11End: 2019-01-14Updated: 2019-04-24

Unknown Phase

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE

TerminatedNCT00578539

Baylor College of MedicineHodgkin Lymphoma, Leukemia, Myeloproliferative Disorders +1

Start: 2007-10-31End: 2013-05-31Updated: 2016-04-22

T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE

TerminatedNCT00578461

Baylor College of MedicineCancer, Leukemia, Lymphoma +2

Start: 2007-10-31End: 2013-05-31Updated: 2016-04-22

Related Papers

P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY

HemaSphere2022-06-01

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Blood2016-12-0247 citations

Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Blood2015-12-0320 citations

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

2011-03-31203 citations